Advertisement
Advertisement

RIGL

RIGL logo

Rigel Pharmaceuticals Inc. (New)

34.19
USD
Sponsored
+0.97
+2.93%
Feb 06, 16:00 UTC -5
Closed
exchange

After-Market

34.20

0.00
+0.01%

RIGL Earnings Reports

Positive Surprise Ratio

RIGL beat 30 of 40 last estimates.

75%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$69.28M
/
$1.18
Implied change from Q3 25 (Revenue/ EPS)
-0.26%
/
-19.18%
Implied change from Q4 24 (Revenue/ EPS)
+20.29%
/
+47.50%

Rigel Pharmaceuticals Inc. (New) earnings per share and revenue

On Nov 04, 2025, RIGL reported earnings of 1.46 USD per share (EPS) for Q3 25, beating the estimate of 0.87 USD, resulting in a 67.47% surprise. Revenue reached 69.46 million, compared to an expected 63.12 million, with a 10.05% difference. The market reacted with a +33.37% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of 1.18 USD, with revenue projected to reach 69.28 million USD, implying an decrease of -19.18% EPS, and decrease of -0.26% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Rigel Pharmaceuticals Inc. (New) reported EPS of $1.46, beating estimates by 67.47%, and revenue of $69.46M, 10.05% above expectations.
The stock price moved up 33.37%, changed from $28.38 before the earnings release to $37.85 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 7 analysts, Rigel Pharmaceuticals Inc. (New) is expected to report EPS of $1.18 and revenue of $69.28M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement